5/29/2014 9:07:57 AM
RESEARCH TRIANGLE PARK, N.C., May 28, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $10.00 per share. The gross proceeds from this offering to BioCryst are expected to be $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst. BioCryst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock. The offering is expected to close on or about June 3, 2014, subject to customary closing conditions. BioCryst expects to use the net proceeds of this offering for general corporate purposes, including funding clinical development of BCX4161, the development of both second generation hereditary angioedema compounds, commercialization activities relating to peramivir and the advancement of other preclinical rare disease programs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by